AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03724955
Drug: Estradiol 2 mg
RxNorm normalized name: estradiol 2 MG
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in this arm will receive Estradiol 2 mg oral daily for 6 months
Trial: NCT02679729
Drug: AZD5634 for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer
Trial: NCT02679729
Drug: AZD5634 for infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, citrate buffer, saline solution for infusion; strength 0.013 mg/mL
Trial: NCT00114504
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 5-10 mg/day
Trial: NCT01576458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02993562
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Normal treatment with levothyroxine.
Trial: NCT00003953
Drug: CMF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratum I and II: receive cyclophosphamide, methotrexate, and fluorouracil (CMF) for 4 courses
Trial: NCT00002581
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002581
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003953
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin IV on days 1, 15, and 29.
Trial: NCT00002581
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01658657
Drug: lisinopril/hydrochlorothiazide
RxNorm normalized name: lisinopril/hydrochlorothiazide 20 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a combination pill
Trial: NCT01044186
Drug: ICL670
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04411680
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care for COVID-19
Trial: NCT01535053
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01535053
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV and IM
Trial: NCT04381598
Drug: stevia rebaudiana bertoni
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stevia has an anti-plaque effect because of its ability in decreasing the formation of bacterial insoluble polymers.It significantly decreases the production of TNF-R and IL-1a and slightly decreases the production of NO in stimulated cells with LPS and THP-1 showing its anti-inflammatory properties.These characteristics in combination with anti-diabetic properties could results in the effective treatment of periodontal diseases.
Trial: NCT02373462
Drug: other anti-hypertensive drug
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCB, diuretics, alpha blocker, direct vasodilator, beta blocker
Trial: NCT06241222
Drug: Probiotic Blend Oral Tablet
RxNorm normalized name: Probiotic Blend Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In our study, fourteen pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 ∗ 106 CFU), Lactobacillus delbrueckii bulgaricus (5 ∗ 105 CFU) and Streptococcus thermophilus (5 ∗ 105 CFU) tablets produced by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered two tablets twice a day (2 g/d) until natural delivery
Trial: NCT01124786
Drug: CO-1.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1250 mg/m2 intravenous infusion weekly for 3 weeks every 4 weeks
Trial: NCT03245658
Drug: THC and CBD Mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individually titrated doses on daily basis
Trial: NCT00354419
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00284518
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline (Placebo) transperineal or transrectal injection on Day 1.
Trial: NCT04883996
Drug: 1% EXP039
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% EXP039 (commercially available as Isopto® Carpine) contains 1% active ingredient (10 mg/mL),
Trial: NCT03777878
Drug: placebo to TA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo ampoules to TA in 100 ml saline by slow infusion
Trial: NCT03046550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00111345
Drug: Anthracyclines
RxNorm normalized name: Anthracyclines and related substances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x12 mg/qm
Trial: NCT02386358
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo at a dose 5 m/Kg/day until 60 days
Trial: NCT00694408
Drug: methyl prednisolone, hydrocortisone, prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be specific dependant on weight of patients
Trial: NCT00750243
Drug: LT-NS001
RxNorm normalized name: LT KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg b.i.d. p.o. for 7.5 days
Trial: NCT00750243
Drug: Naprosyn®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg b.i.d. p.o. for 7.5 days
Trial: NCT00872534
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 325mg once a day for 7 days
Trial: NCT02734940
Drug: Unrestricted Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: No changes to current practices, using unlimited narcotic medications intraoperatively.
Trial: NCT00987220
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03188445
Drug: ferrous fumarate with ascorbic acid
RxNorm normalized name: ascorbic acid / ferrous fumarate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT06040372
Drug: LB64640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational product (IP) LB54640 is provided 5 mg, 25 mg and 200 mg strengths.
Trial: NCT06040372
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is provided as a matching placebo
Trial: NCT00931489
Drug: ranibizumab (Lucentis(R))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg intravitreal injection once a month for 4 months, then as needed for 2 months
Trial: NCT04272437
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the placebo group orally ingested one package of granules (5 g/package) two times daily with warm water after lunch and dinner for 6 consecutive weeks.
Trial: NCT02974907
Drug: RGN-259
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
Trial: NCT02974907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is composed of the same excipients as RGN-259 but does not contain Tβ4
Trial: NCT02331511
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo administration for 3 months after device(PPM,ICD,CRT) implantation
Trial: NCT01430533
Drug: Vehicle pre foam formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02420353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo diluent that will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of the equivalent concentration of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take medication, but otherwise patients will take medication every day over this 6 week period.
Trial: NCT01293097
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care, but statin dose should not be higher than that described in exclusion criteria
Trial: NCT00471510
Drug: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
RxNorm normalized name: tetrapeptide-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study preparation (experimental, placebo comparator) will be applied to the scalp once daily for 16 weeks
Trial: NCT03169816
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo for lorcaserin condition dosed twice daily
Trial: NCT03499873
Drug: Nepafenac 0.3% Oph Susp
RxNorm normalized name: NEPAFENAC 0.3% OPH SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nepafenac 0.3% Ophthalmic suspension (experimental product)
Trial: NCT03499873
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03499873
Drug: Nepafenac 0.3% Oph Susp (reference)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nepafenac 0.3% Ophthalmic suspension (Innovator)
Trial: NCT03630627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously
Trial: NCT01652898
Drug: LDLA202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of 3 different doses LDLA202, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
Trial: NCT04275115
Drug: Drug Cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of the cocktail probe substrates (caffeine 200 mg, montelukast 10 mg, midazolam 4 mg)
Trial: NCT01166113
Drug: Pomalidomide, Cyclophosphamide, Prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction~This multicenter phase I followed by a phase II trial will evaluate the safety and efficacy of the combination Pomalidomide-Cyclophosphamide-Prednisone (PCP) in patients (pts) with MM relapsed/refractory to lenalidomide.~In the phase I we assess the maximum tolerated dose (MTD) of PCP in 25% of pts. The first 4 pts are given the second dose level, accrual continues with 4 pts per dose level for a maximum of 24 pts.~The dose level associated with an updated DLT is recommended for the next patient cohort.~Each patient is assigned to a salvage therapy including Cyclophosphamide and Prednisone (both 50 mg every other d), and Pomalidomide at one of the following doses:1 mg/d;1.5 mg/d;2 mg/d;2.5 mg/d~In the phase II a total of 43 pts will be treated with the MTD of PCP. Pts enrolled at the MTD during the phase I will be included in the Phase II trial.~Maintenance (each cycle repeated every 28 d, until PD) Pomalidomide: 2.5 mg/d; Prednisone: 25 mg every other d
Trial: NCT01929278
Drug: CT Gel (clindamycin 1% and tretinoin 0.025%)
RxNorm normalized name: tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three CT Gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures.
Trial: NCT01143337
Drug: MP-435(dose1) + Methotrexate
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MP-435 dose1 + stable weekly dose of Methotrexate
Trial: NCT01143337
Drug: Placebo + Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + stable weekly dose of Methotrexate
Trial: NCT02761915
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02294305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02899156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline
Trial: NCT01828203
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01828203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04371224
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NaliCap
Trial: NCT04371224
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NAPOLI
Trial: NCT01345539
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy choice of agents is at the discretion of the treating medical oncologist.
Trial: NCT00983996
Drug: Fosamax Tablets, 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg, single-dose fasting
Trial: NCT01493180
Drug: OPC-12759 ophthalmic suspension
RxNorm normalized name: Opcon-A Ophthalmic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-12759 ophthalmic suspension 2%
Trial: NCT01045720
Drug: Suo Quan Wan, Wu Lin San
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suo Quan Wan Wu Lin San Placebo 2/daily
Trial: NCT01045720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch)
Trial: NCT00218465
Drug: Placebo Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02674529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03506178
Drug: Normal saline Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
Trial: NCT02035878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator
Trial: NCT01261767
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for subcutaneous (under the skin) injection
Trial: NCT03205033
Drug: Melatonin 20 MG Oral Capsule
RxNorm normalized name: melatonin 20 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule/day 1 hour before go to bed
Trial: NCT03205033
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule/day 1 hour before go to bed
Trial: NCT03385863
Drug: Surfactant, Pulmonary，Curosurf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All NRDS were given an early endotracheal infusion of Curosuf, with an initial dose of 200mg/kg, and if the condition needed to be repeated. Compare the therapeutic effect of pulmonary surfactant of infants at different gestational ages and to investigate whether exogenous surfactant replacement therapy is effective for all newborns with RDS.
Trial: NCT02966028
Drug: SNF472
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
Trial: NCT02966028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
Trial: NCT00854477
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: film-coated tablet 1250 mg/m2 twice daily for 14 days every 3 weeks. Number of cycles: 8 cycles unless there is evidence of disease progression, or unacceptable toxicity
Trial: NCT02936570
Drug: BAY987521
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-067)
Trial: NCT00102726
Drug: SB497115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB497115/Placebo will be administered for at least 2 cycles. Additional cycles are permited if: 1) chemotherapy is continued, 2) the subject appears to be benefitting from the study drug, and 3) the subject has not encountered greater than moderate toxicity with the study drug. The maximum number of cycles would be 8.
Trial: NCT02721563
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo:three times a week (once every other one day),before radiation therapy, total 6 weeks.
Trial: NCT01502904
Drug: pravastatin 20mg/day after DES implantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
Trial: NCT01502904
Drug: Non-ARB /day after DES implantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
Trial: NCT01502904
Drug: Eposartan 600mg/day after DES implantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
Trial: NCT04062175
Drug: Azithromycin Tablets
RxNorm normalized name: Azithromycin Tablets
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 72 women will receive combined antibiotic chemotherapy azithromycin(Azrolid) 1 gm single oral dose 2 hours before cesarean delivery +cephalosporin(Cefazolin) 2 gm iv within 30 minutes before skin incision
Trial: NCT02887885
Drug: Gynoflor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 vaginal tablet daily for 12 days, followed by 3 vaginal tablets per week as maintenance therapy (Monday-Wednesday-Friday) for 6 weeks
Trial: NCT00517998
Drug: Biologic Lung Volume Reduction (BLVR) - 10 mL Hydrogel
RxNorm normalized name: REDUCTIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL Hydrogel
Trial: NCT00654498
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01401504
Drug: ASP3026
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02795078
Drug: conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03504475
Drug: Paxil® 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paxil® Tablet 20 mg will be used as a comparator drug for the bioequivalence study, manufactured by GlaxoSmithKline（Distributed by: Apotex Corp.）.
Trial: NCT01479517
Drug: Kovacaine Mist 0.1 mL x 4 sprays
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose = 4 intranasal sprays of study drug delivered at 4-minute intervals.
Trial: NCT01479517
Drug: Kovacaine Mist 0.2 mL x 2 sprays
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose = 2 intranasal sprays of study drug delivered at 4-minute intervals.
Trial: NCT01479517
Drug: Kovacaine Mist 0.2 mL x 1 spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose = 1 intranasal spray of study drug
Trial: NCT02038023
Drug: Intravaneous iron(low molecular weight iron dextran)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of Iron dextran administered over one hour
Trial: NCT01726933
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
Trial: NCT01456247
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
Trial: NCT02995135
Drug: BAY987517
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z43-094)
Trial: NCT01456247
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
Trial: NCT01277835
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline Infusion at same rate as experimental arm
Trial: NCT02965261
Drug: Torrent's Fluoxetine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02965261
Drug: Warner Chilcott LLC Sarafem Tablets
FDA approved: no
EMA approved: no
PMDA approved: no